40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Ryght AI tackles these hurdles with its AI Site Twin platform
Growing patent filings and tier-2 innovators reflect expanding national research base
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
The initiative aims to connect startups and tech companies with its business units,
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
Subscribe To Our Newsletter & Stay Updated
